![Ilan Oren](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ilan Oren
Vorsitzender bei
ROIVANT SCIENCES LTD.
Vermögen: 4 Mio $ am 31.07.2026
Profil
Mr. Ilan Oren is an Independent Chairman at Roivant Sciences Ltd., a Co-Chief Executive Officer at Dexcel Pharma Technologies Ltd. and a Co - CEO at Dexcel Ltd. He is on the Board of Directors at Kriya Therapeutics, Inc., 8400 - The Health Network, Clexio Biosciences Ltd. and Roivant Sciences, Inc. Mr. Oren was previously employed as a Non-Executive Director by Axovant Gene Therapies Ltd., an Independent Director by Cynapsus Therapeutics, Inc., and an Independent Director by Montes Archimedes Acquisition Corp.
He also served on the board at Axovant Gene Therapies Ltd. He received his undergraduate degree from Harvard College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ROIVANT SCIENCES LTD. 0,02 % | 17.07.2026 | 121.004 ( 0,02 % ) | 4 Mio $ | 31.07.2026 |
Aktive Positionen von Ilan Oren
| Unternehmen | Position | Beginn |
|---|---|---|
| ROIVANT SCIENCES LTD. | Vorsitzender | 13.03.2023 |
Dexcel Pharma Technologies Ltd.
 Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes generic pharmaceuticals products | Vorstandsvorsitzender | 01.11.2019 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Direktor/Vorstandsmitglied | - |
Kriya Therapeutics, Inc.
 Kriya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing gene therapies for treatment of chronic diseases | Direktor/Vorstandsmitglied | 01.01.2020 |
Clexio Biosciences Ltd.
 Clexio Biosciences Ltd. Pharmaceuticals: OtherHealth Technology Develops novel therapies for patients suffering from neurological and psychiatric conditions | Direktor/Vorstandsmitglied | 01.01.2018 |
8400 - The Health Network
 8400 - The Health Network Miscellaneous Commercial ServicesCommercial Services The private company is based in Raanana, Israel. It comprises a collective of around 400 healthtech leaders from academia, industry, government, healthcare organizations, and NGOs who collaborate to accelerate healthcare innovation, commercialization, and ecosystem development. Key initiatives include the 8400 leadership program, an intensive fellowship developed with partners such as Harvard Business School Executive Education and Israeli government bodies, designed to cultivate healthtech leadership and foster collaborations. Graduates become active network members engaged in national programs and ecosystem growth projects. The network operates a programs incubator focusing on six critical clusters—talent and skills, infrastructure and resources, funding, policy and regulation, tech transfer, and multinationals and network—to address ecosystem gaps and leverage opportunities. Projects include HealthIL, which has facilitated pilots bridging healthcare and technology, and the Israeli FHIR community (FHIR-IL), promoting standardized healthcare data exchange. 8400 also leads bi-national efforts and initiatives supporting venture formation, commercialization, and cross-border collaboration between Israeli and healthtech sectors. 8400 - The Health Network is an organization founded in 2017 dedicated to advancing Israel’s healthtech and life sciences industry as a major engine for economic growth and health innovation. | Direktor/Vorstandsmitglied | 01.01.2019 |
Dexcel Ltd.
 Dexcel Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets generic pharmaceuticals | Private Equity Investor | - |
Ehemalige bekannte Positionen von Ilan Oren
| Unternehmen | Position | Ende |
|---|---|---|
| SIO GENE THERAPIES INC. | Direktor/Vorstandsmitglied | 24.09.2020 |
| SIO GENE THERAPIES INC. | Direktor/Vorstandsmitglied | 21.12.2017 |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Ilan Oren
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
61
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Cynapsus Therapeutics, Inc.
 Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Health Technology |
Roivant Sciences Ltd.
 Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
Dexcel Ltd.
Dexcel Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets generic pharmaceuticals | Health Technology |
Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes generic pharmaceuticals products | Health Technology |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Clexio Biosciences Ltd.
Clexio Biosciences Ltd. Pharmaceuticals: OtherHealth Technology Develops novel therapies for patients suffering from neurological and psychiatric conditions | Health Technology |
Kriya Therapeutics, Inc.
Kriya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing gene therapies for treatment of chronic diseases | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
8400 - The Health Network
8400 - The Health Network Miscellaneous Commercial ServicesCommercial Services The private company is based in Raanana, Israel. It comprises a collective of around 400 healthtech leaders from academia, industry, government, healthcare organizations, and NGOs who collaborate to accelerate healthcare innovation, commercialization, and ecosystem development. Key initiatives include the 8400 leadership program, an intensive fellowship developed with partners such as Harvard Business School Executive Education and Israeli government bodies, designed to cultivate healthtech leadership and foster collaborations. Graduates become active network members engaged in national programs and ecosystem growth projects. The network operates a programs incubator focusing on six critical clusters—talent and skills, infrastructure and resources, funding, policy and regulation, tech transfer, and multinationals and network—to address ecosystem gaps and leverage opportunities. Projects include HealthIL, which has facilitated pilots bridging healthcare and technology, and the Israeli FHIR community (FHIR-IL), promoting standardized healthcare data exchange. 8400 also leads bi-national efforts and initiatives supporting venture formation, commercialization, and cross-border collaboration between Israeli and healthtech sectors. 8400 - The Health Network is an organization founded in 2017 dedicated to advancing Israel’s healthtech and life sciences industry as a major engine for economic growth and health innovation. | Commercial Services |
